Year Book of Endocrinology 2014

Schott Matthias

Description

The Year Book of Endocrinology brings you abstracts of the articles that reported the year's breakthrough developments in endocrinology carefully selected from more than 500 journals worldwide. Expert commentaries evaluate the clinical importance of each article and discuss its application to your practice. Topics such as Diabetes, Lipoproteins and Ahterosclerosis, Obesity, Thyroid, Calcium and Bone Metabolism, Adrenal Cortex, and Neuroendocrinology are represented highlighting the most current and relevant articles in the field.

Sujets

• Médecine
• Spécialités médicales
• Medical
• Metabolism
• Endocrinology

Informations

• Publié par: Elsevier
• Date de parution: 30 octobre 2015
• Nombre de lectures: 0
• EAN13: 9780323264969
• Langue: English
• Poids de l'ouvrage: 2 Mo

Extrait

Year Book
Year Book of Endocrinology 2014

MATTHIAS SCHOTT
BART L. CLARKE
ERICA A. EUGSTER
LALITA KHAODHIAR
A. WAYNE MEIKLE
ELKE OETJEN
STEPHAN PETERSENN
PETER P. TOTH
HOLGER S. WILLENBERG
ISSN  0084-3741 Volume 2014 • Number suppl (C) • 2014
Elsevier
Table of Contents
Cover image
Title page
1. DIABETES
1.1 Complications
Glucose Levels and Risk of Dementia
Abstract
Commentary
An association between gestational diabetes mellitus and long-term maternal cardiovascular morbidity
Abstract
Commentary
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Abstract
Commentary
Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation
Abstract
Commentary
Changing Impact of Modifiable Risk Factors on the Incidence of Major Outcomes of Type 1 Diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study
Abstract
Commentary
1.2. Glycemic Control
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP
Abstract
Commentary
Liver-Derived Systemic Factors Drive β Cell Hyperplasia in Insulin-Resistant States
Abstract
Commentary
11β-HSD1 Inhibitors for the Treatment of Type 2 Diabetes and Cardiovascular Disease
Abstract
Commentary
Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors
Abstract
Commentary
Evaluation of the dual peroxisome proliferator–activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: Rationale and design of the AleCardio trial
Abstract
Commentary
An inhibitor of the protein kinases TBK1 and IKK-ε improves obesity-related metabolic dysfunctions in mice
Abstract
Commentary
Salicylate (Salsalate) in Patients With Type 2 Diabetes: A Randomized Trial
Abstract
Commentary
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Abstract
Commentary
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
Abstract
Commentary
Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial
Abstract
Commentary
Marked Expansion of Exocrine and Endocrine Pancreas with Incretin Therapy in Humans with Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Abstract
Commentary
A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
Abstract
Commentary
1.3. Pathogenesis
Betatrophin: A Hormone that Controls Pancreatic β Cell Proliferation
Abstract
Commentary
Inactivation of specific β cell transcription factors in type 2 diabetes
Abstract
Commentary
1.4. Prevention and Reversal of Diabetes
Achievement of Goals in U.S. Diabetes Care, 1999–2010
Abstract
Commentary
2. LIPOPROTEINS AND ATHEROSCLEROSIS
2.1. Pharmacologic Therapy
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial
Abstract
Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study
Abstract
Relationship of Lipoproteins to Cardiovascular Events: The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With LOW HDL/High Triglycerides and Impact on Global Health Outcomes)
Abstract
Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry)
Abstract
Commentary
Impact of Lipid-Lowering Medications and Low-Density Lipoprotein Levels on 1-Year Clinical Outcomes after Coronary Artery Bypass Grafting
Abstract
Commentary
C-reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy
Abstract
Commentary
AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy: An Analysis From the LDL-C Assessment With Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy (LAPLACE)–Thrombolysis in Myocardial Infarction (TIMI) 57 Trial
Abstract
Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication
Abstract
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
Abstract
Commentary
2.2. Prevention of Atherosclerosis
High-Density Lipoprotein Mediated Cellular Cholesterol Efflux in Acute Coronary Syndromes
Abstract
Commentary
Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting
Abstract
2.3. Statin Safety
Lipid-Modifying Therapies and Risk of Pancreatitis: A Meta-analysis
Abstract
Commentary
2.4. Epidemiology and Diagnosis
Body Fat Distribution, Incident Cardiovascular Disease, Cancer, and All-Cause Mortality
Abstract
Low Levels of High-Density Lipoprotein Cholesterol and Increased Risk of Cardiovascular Events in Stable Ischemic Heart Disease Patients: A Post-Hoc Analysis From the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)
Abstract
Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation
Abstract
Commentary
2.5. Metabolic Syndrome
Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
Abstract
Commentary
Prandial Hypertriglyceridemia in Metabolic Syndrome Is Due to an Overproduction of Both Chylomicron and VLDL Triacylglycerol
Abstract
Commentary
3. OBESITY
3.1. New Developments in Obesity
KSR2 Mutations Are Associated with Obesity, Insulin Resistance, and Impaired Cellular Fuel Oxidation
Abstract
Commentary
Myths, Presumptions, and Facts about Obesity
Abstract
Commentary
3.2. Epidemiology and Complications of Obesity
Are Metabolically Healthy Overweight and Obesity Benign Conditions?: A Systematic Review and Meta-Analysis
Abstract
Commentary
3.3. Diet and Obesity
Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
Abstract
Commentary
3.4. Surgical Treatment of Obesity
Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery
Abstract
Commentary
4. THYROID
4.1. Autoimmunity
Reduced Effectiveness of CD4+Foxp3+Regulatory T Cells in CD28-Deficient NOD.H-2h4 Mice Leads to Increased Severity of Spontaneous Autoimmune Thyroiditis
Abstract
Commentary
Changes in Serum Adhesion Molecules, Chemokines, Cytokines, and Tissue Remodeling Factors in Euthyroid Women Without Thyroid Antibodies Who Are at Risk for Autoimmune Thyroid Disease: A Hypothesis on the Early Phases of the Endocrine Autoimmune Reaction
Abstract
4.2. Thyroid Cancer
Differentiated Thyroid Cancer Is Associated With Less Aggressive Disease and Better Outcome in Patients With Coexisting Hashimotos Thyroiditis
Abstract
Does BRAF V600E Mutation Predict Aggressive Features in Papillary Thyroid Cancer? Results From Four Endocrine Surgery Centers
Abstract
Aberrant Overexpression of Pyruvate Kinase M2 Is Associated With Aggressive Tumor Features and the BRAF Mutation in Papillary Thyroid Cancer
Abstract
S100A11 Overexpression Contributes to the Malignant Phenotype of Papillary Thyroid Carcinoma
Abstract
Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease
Abstract
Development of p21 Activated Kinase-Targeted Multikinase Inhibitors That Inhibit Thyroid Cancer Cell Migration
Abstract
Inhibition of AMPK and Krebs Cycle Gene Expression Drives Metabolic Remodeling of Pten-Deficient Preneoplastic Thyroid Cells
Abstract
Commentary
Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers
Abstract
Commentary
Comparative Analysis of the Thyrocytes and T Cells: Responses to H2O2 and Radiation Reveals an H2O2-Induced Antioxidant Transcriptional Program in Thyrocytes
Abstract
Vandetanib in Children and Adolescents with Multiple Endocrine Neoplasia Type 2B Associated Medullary Thyroid Carcinoma
Abstract
Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer
Abstract
4.3. Thyroid Nodules
Comparison of Elastographic Strain Index and Thyroid Fine-Needle Aspiration Cytology in 631 Thyroid Nodules
Abstract
4.4. Thyrotoxicosis
Analysis of 754 Cases of Antithyroid Drug-Induced Agranulocytosis Over 30 Years in Japan
Abstract
4.5. Thyroid Disease in Pregnancy
Effect of inadequate iodine status in UK pregnant women on cognitive outcomes in their children: results from the Avon Longitudinal Study of Parents and Children (ALSPAC)
Abstract
Hypothyroxinemia and TPO-Antibody Positivity Are Risk Factors for Premature Delivery: The Generation R Study
Abstract
Five-Year Follow-Up for Women With Subclinical Hypothyroidism in Pregnancy
Abstract
4.6. Miscellaneous
Histidines in Potential Substrate Recognition Sites Affect Thyroid Hormone Transport by Monocarboxylate Transporter 8 (MCT8)
Abstract
Commentary
Embryonic exposure to excess thyroid hormone causes thyrotrope cell death
Abstract
Commentary
5. CALCIUM AND BONE METABOLISM
5.1 Mineral and Vitamin D Metabolism
Serum 25-Hydr